MX2020003670A - Metodos para tratar infecciones bacterianas. - Google Patents

Metodos para tratar infecciones bacterianas.

Info

Publication number
MX2020003670A
MX2020003670A MX2020003670A MX2020003670A MX2020003670A MX 2020003670 A MX2020003670 A MX 2020003670A MX 2020003670 A MX2020003670 A MX 2020003670A MX 2020003670 A MX2020003670 A MX 2020003670A MX 2020003670 A MX2020003670 A MX 2020003670A
Authority
MX
Mexico
Prior art keywords
subject
methods
subjects
transplant
bone marrow
Prior art date
Application number
MX2020003670A
Other languages
English (en)
Spanish (es)
Inventor
Michael N Dudley
Elizabeth Alexander
Jeff Loutit
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65994826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020003670(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of MX2020003670A publication Critical patent/MX2020003670A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020003670A 2017-10-03 2018-10-01 Metodos para tratar infecciones bacterianas. MX2020003670A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762567702P 2017-10-03 2017-10-03
US201862657402P 2018-04-13 2018-04-13
PCT/US2018/053772 WO2019070591A1 (en) 2017-10-03 2018-10-01 METHODS OF TREATING BACTERIAL INFECTIONS

Publications (1)

Publication Number Publication Date
MX2020003670A true MX2020003670A (es) 2020-08-03

Family

ID=65994826

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003670A MX2020003670A (es) 2017-10-03 2018-10-01 Metodos para tratar infecciones bacterianas.

Country Status (16)

Country Link
US (3) US11376237B2 (https=)
EP (1) EP3691652A4 (https=)
JP (1) JP2020536092A (https=)
KR (1) KR20200066664A (https=)
CN (1) CN111432821A (https=)
AU (1) AU2018345317B2 (https=)
BR (1) BR112020006658A2 (https=)
CA (1) CA3078238A1 (https=)
CL (1) CL2020000892A1 (https=)
JO (1) JOP20200075A1 (https=)
MX (1) MX2020003670A (https=)
MY (1) MY200934A (https=)
PH (1) PH12020550249A1 (https=)
SG (1) SG11202003009QA (https=)
TW (2) TW202400146A (https=)
WO (1) WO2019070591A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020006658A2 (pt) * 2017-10-03 2020-09-24 Melinta Therapeutics, Inc. métodos de tratamento de infecções bacterianas
TW202304469A (zh) * 2021-03-24 2023-02-01 美商杜夫特學院信託管理公司 酸化合物、組合物及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101912363A (zh) 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
RS60310B1 (sr) 2010-08-10 2020-07-31 Rempex Pharmaceuticals Inc Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe
CN102188395B (zh) 2011-04-29 2012-12-05 石药集团中诺药业（石家庄）有限公司 一种更稳定的美罗培南注射剂及其制备方法
CN102335137B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种含美罗培南的药物组合物
CN102335136B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种供注射用美罗培南药物组合物及其制备方法
CN102525961B (zh) 2012-01-17 2013-02-13 山东罗欣药业股份有限公司 美罗培南组合物注射用粉针剂
US10561675B2 (en) * 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN103570718B (zh) 2012-07-31 2016-06-29 深圳市海滨制药有限公司 一种美罗培南原料药、其制备方法及包含其的药物组合物
US9993469B2 (en) 2013-05-28 2018-06-12 Morphochem Aktiengesellschaft Für Kombinatorishe Chemie Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections
ES2942329T3 (es) * 2015-04-24 2023-05-31 Melinta Therapeutics Inc Régimen de dosificación de vaborbactam y meropenem para el tratamiento de infecciones bacterianas en sujetos con función renal reducida
JP6845511B2 (ja) 2015-07-09 2021-03-17 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 抗細菌性薬剤併用物の組成物及び使用方法
US9949995B2 (en) 2015-09-04 2018-04-24 Case Western Reserve University Compositions and methods of treating of bacterial infections with β-lactamase inhibitors
MX390529B (es) 2017-01-09 2025-03-20 Rempex Pharmaceuticals Inc Metodos para tratar infecciones bacterianas
BR112020006658A2 (pt) 2017-10-03 2020-09-24 Melinta Therapeutics, Inc. métodos de tratamento de infecções bacterianas

Also Published As

Publication number Publication date
CA3078238A1 (en) 2019-04-11
US11376237B2 (en) 2022-07-05
EP3691652A1 (en) 2020-08-12
CL2020000892A1 (es) 2020-10-23
US20200297695A1 (en) 2020-09-24
JOP20200075A1 (ar) 2020-04-30
KR20200066664A (ko) 2020-06-10
TW201922241A (zh) 2019-06-16
CN111432821A (zh) 2020-07-17
JP2020536092A (ja) 2020-12-10
US20260102374A1 (en) 2026-04-16
US12533342B2 (en) 2026-01-27
BR112020006658A2 (pt) 2020-09-24
TW202400146A (zh) 2024-01-01
AU2018345317A1 (en) 2020-05-07
SG11202003009QA (en) 2020-04-29
EP3691652A4 (en) 2021-07-07
US20220288024A1 (en) 2022-09-15
AU2018345317B2 (en) 2024-10-24
PH12020550249A1 (en) 2021-02-15
WO2019070591A1 (en) 2019-04-11
MY200934A (en) 2024-01-24

Similar Documents

Publication Publication Date Title
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
CL2022001752A1 (es) Compuesto de piridazinil-tiazolcarboxamida
CY1125242T1 (el) Κυτταροκαλλιεργεια
EA202191632A1 (ru) Ахромосомные динамические активные системы
NZ742208A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
MX2021000719A (es) Composicion de microbiota fecal, para su uso en la reduccion de la inflamacion inducida por tratamiento.
ES2525137B1 (es) Agentes para tratar el mieloma múltiple
PH12017501300A1 (en) Novel iodophor composition and methods of use
WO2018009528A8 (en) Combination cancer immunotherapies with arginine depletion agents
CL2018001913A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
MX393900B (es) Uso de gaboxadol en el tratamiento de tinnitus.
CL2020001464A1 (es) Péptidos antimicrobianos y métodos para usarlos.
CL2018001911A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
ECSP18060864A (es) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
CL2019001918A1 (es) Métodos para tratar infecciones bacterianas.
MX2020003670A (es) Metodos para tratar infecciones bacterianas.
WO2020072519A8 (en) Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
EP4461314A3 (en) Methods and materials for killing hiv infected cells
MX2024005589A (es) Combinaciones de lurbinectedina y atezolizumab.
GEAP202215466A (en) Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment
BR112019001130A2 (pt) uso de lactama e composição farmacêutica
CL2019003172A1 (es) Brimonidina destinada al uso y diseño de ensayos clínicos para la atrofia geográfica debido a una degeneración macular asociada a la edad.
MX2024003331A (es) Moleculas de union a d3 y usos de estas.
MX2020006368A (es) Uso de tratamiento combinado de anticuerpo pd-1 y apatinib para tratar cancer de mama triple negativo.